FRONTOTEMPORAL DEMENTIA

This early-stage study is testing an investigational drug called DNL593 to see if it is safe and how it behaves in the body. It involves healthy volunteers and people diagnosed with frontotemporal dementia (FTD) who have a specific genetic mutation. The main goal is to check for …

This study is testing whether metformin, a common diabetes medication, is safe and tolerable for people with a specific genetic form of ALS caused by a C9orf72 mutation. Researchers want to see if taking metformin for 24 weeks can reduce levels of harmful proteins in the brain an…

This is an early-stage study testing a new gene therapy called LY3884963 for people with a specific genetic form of frontotemporal dementia (FTD). The main goals are to check if the treatment is safe and to see if it can increase levels of a protective protein in the brain and sp…

This study explores whether doing rhythmic music activities together can improve social attention and feelings of connection for people with mild to moderate frontotemporal dementia or Alzheimer's disease and their caregivers. Researchers will compare groups doing synchronized mu…

This study aims to collect feedback from people with neurological diseases and their caregivers about their experience using the MemorEM head device. About 1,000 participants with conditions like Alzheimer's or Parkinson's will use the device at home and complete monthly surveys.…

This study aims to find and validate biological markers (biomarkers) in blood, urine, and spinal fluid from people with ALS and related disorders. The goal is to better understand the diseases and create tools to measure if future experimental treatments are working. It involves …

This study aims to develop and test a remote monitoring system for people with frontotemporal dementia and related disorders like Progressive Supranuclear Palsy (PSP). Researchers will enroll 60 participants with PSP and follow them for 12 months using wearable sensors and mobile…

This study aims to track a specific protein in the blood (neurofilament light chain) over three years in people who carry a genetic risk for frontotemporal dementia (FTD). It involves 342 participants who will have blood drawn remotely four times a year. The goal is to see if thi…